Translational Lung Cancer Research

Scope & Guideline

Bridging laboratory discoveries to clinical excellence.

Introduction

Delve into the academic richness of Translational Lung Cancer Research with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2218-6751
PublisherAME PUBLISHING COMPANY
Support Open AccessNo
CountryHong Kong
TypeJournal
Convergefrom 2012 to 2024
AbbreviationTRANSL LUNG CANCER R / Transl. Lung Cancer Res.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressFLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA

Aims and Scopes

Translational Lung Cancer Research aims to advance the understanding and treatment of lung cancer through innovative research and clinical studies, focusing on a wide range of topics related to diagnosis, treatment, and patient management.
  1. Clinical Research and Trials:
    The journal publishes studies related to clinical trials assessing the efficacy and safety of various treatments for lung cancer, including chemotherapy, immunotherapy, and targeted therapies.
  2. Biomarkers and Genomics:
    Research on the identification and validation of biomarkers for early detection, prognostication, and treatment response in lung cancer, emphasizing genomic alterations and their implications.
  3. Radiology and Imaging:
    Papers that explore advancements in imaging techniques, including CT, PET, and radiomics, to enhance diagnostic accuracy and guide treatment decisions.
  4. Patient-Centered Care:
    Studies focusing on the quality of life, psychological impact, and socioeconomic factors affecting lung cancer patients, including screening programs and survivorship.
  5. Innovative Therapeutic Approaches:
    Research on novel therapies and combinatorial approaches, including immunotherapy and personalized medicine, aimed at overcoming resistance and improving patient outcomes.
  6. Surgical Techniques and Outcomes:
    Publications detailing advancements in surgical procedures, including minimally invasive techniques, their efficacy, and associated outcomes.
  7. Epidemiology and Risk Factors:
    Research addressing the epidemiological aspects of lung cancer, including risk factors, demographics, and trends in incidence and mortality.
The journal has identified several emerging themes that reflect current trends in lung cancer research, indicating a dynamic shift towards innovative methodologies and patient-centered approaches.
  1. Immunotherapy and Combination Therapies:
    There is a significant increase in research focusing on immunotherapy, particularly combination therapies that integrate immune checkpoint inhibitors with other treatments to enhance efficacy.
  2. Liquid Biopsy and Circulating Biomarkers:
    Studies on liquid biopsy techniques and circulating tumor DNA (ctDNA) are gaining momentum, offering non-invasive methods for monitoring treatment responses and disease progression.
  3. Artificial Intelligence in Diagnostics:
    The integration of AI and machine learning in the analysis of imaging and genomic data is emerging as a powerful tool for improving diagnostic accuracy and personalizing treatment plans.
  4. Real-World Evidence Studies:
    An increasing number of publications are focusing on real-world data to evaluate treatment effectiveness and patient outcomes outside of controlled clinical trial settings.
  5. Health Disparities and Access to Care:
    Research addressing health disparities in lung cancer screening and treatment access is gaining traction, highlighting the need for equitable healthcare solutions.
  6. Microbiome Research:
    Exploration of the role of the microbiome in lung cancer development and treatment response is emerging as a novel area of investigation, linking systemic health with cancer outcomes.

Declining or Waning

While some areas of research continue to thrive, others have shown a decline in focus within the journal, reflecting shifts in the scientific landscape and clinical priorities.
  1. Traditional Chemotherapy Studies:
    As targeted therapies and immunotherapy gain prominence, traditional chemotherapy studies are becoming less frequent, indicating a shift towards more innovative treatment modalities.
  2. Basic Science and Preclinical Studies:
    There is a noticeable reduction in purely basic science studies that do not directly translate to clinical applications, as the journal increasingly prioritizes translational research.
  3. General Epidemiological Surveys:
    Research focusing on broad epidemiological surveys without specific interventions or novel insights is declining, as more targeted and actionable studies are favored.
  4. Non-Clinical Patient Experience Studies:
    Papers focusing on non-clinical aspects of patient experience, such as general quality of life without specific cancer-related interventions, are diminishing in frequency.

Similar Journals

ONCOLOGY RESEARCH

Advancing the Frontiers of Cancer Research
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

CANCER INVESTIGATION

Exploring the frontiers of cancer research with precision.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Cancers

Exploring the frontiers of cancer biology and therapy.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Journal of Bone Oncology

Pioneering Discoveries in Bone Malignancies
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Journal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.

BRITISH JOURNAL OF CANCER

Connecting Researchers and Clinicians in the Fight Against Cancer.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Elevating Clinical Oncology through Rigorous Scholarship.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Molecular and Clinical Oncology

Exploring new frontiers in molecular and clinical oncology.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

INTERNATIONAL JOURNAL OF CANCER

Leading the charge in innovative cancer solutions.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

Chinese Journal of Cancer Research

Shaping the future of oncology through rigorous scholarship.
Publisher: CHINESE JOURNAL CANCER RESEARCH COISSN: 1000-9604Frequency: 4 issues/year

Chinese Journal of Cancer Research, published by Chinese Journal Cancer Research Co, is a pivotal platform for disseminating significant findings in the field of oncology. Since its inception in 1988, the journal has provided a comprehensive forum for cancer research, featuring peer-reviewed articles that cover various aspects of cancer biology, prevention, diagnosis, and treatment. Although the journal's coverage is currently discontinued in Scopus and holds an HIndex that has not been specified, it is ranked in the 65th percentile in Medicine - Oncology and the 48th percentile in Biochemistry, Genetics and Molecular Biology - Cancer Research. This reflects its commitment to maintaining quality and relevance in the rapidly evolving field of cancer research. Researchers, professionals, and students are encouraged to explore its rich archive of studies and breakthroughs to enhance their understanding and further their research. For access, the publication remains instrumental for those invested in advancing the global fight against cancer.

Journal of Cancer

Innovative insights for a cancer-free future.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.